{"hands_on_practices": [{"introduction": "The efficacy of any targeted therapy begins with its ability to bind specifically to its intended molecular targets. For a Bispecific T Cell Engager (BiTE), this involves a precise interaction with both a tumor-associated antigen and the CD3 complex on T cells. This exercise grounds your understanding in the fundamental principles of chemical kinetics, guiding you to derive the relationship between the kinetic rate constants ($k_{\\text{on}}$ and $k_{\\text{off}}$) and the equilibrium dissociation constant ($K_D$) from the law of mass action [@problem_id:2837351]. Mastering this connection is crucial for interpreting binding affinity data and appreciating how molecular-level interactions dictate a drug's overall potency.", "problem": "A bispecific T cell engager (BiTE) molecule has two independent monovalent binding interfaces: one engages the T cell receptor CD3 complex (CD3) on a T cell, and the other engages a tumor-associated antigen (TA) on a target cell. Under conditions of low surface density and sufficient dilution such that rebinding and avidity effects are negligible, each arm can be modeled as a separate reversible bimolecular association with $1{:}1$ stoichiometry. Consider the generic reaction scheme $A + B \\rightleftharpoons C$, where $A$ denotes the free antigen, $B$ denotes the free BiTE arm, and $C$ denotes the arm–antigen complex. The forward microscopic association rate constant is $k_{\\text{on}}$ with units $\\mathrm{M^{-1}\\,s^{-1}}$, and the reverse microscopic dissociation rate constant is $k_{\\text{off}}$ with units $\\mathrm{s^{-1}}$.\n\nStarting from the law of mass action for $A + B \\rightleftharpoons C$, do the following without invoking any pre-memorized shortcut formulas:\n\n1. Define the differential rate equation for the time evolution of the complex concentration $[C](t)$ in terms of $k_{\\text{on}}$, $k_{\\text{off}}$, $[A]$, $[B]$, and $[C]$.\n\n2. Using the definition of chemical equilibrium and the thermodynamic definition of the equilibrium dissociation constant $K_D$ for $A + B \\rightleftharpoons C$, derive an expression for $K_D$ in terms of $k_{\\text{on}}$ and $k_{\\text{off}}$ that applies separately to each BiTE arm.\n\n3. For the CD3-binding arm, the measured kinetic constants are $k_{\\text{on,CD3}} = 2.8 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\text{off,CD3}} = 3.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$. For the tumor antigen-binding arm, the measured kinetic constants are $k_{\\text{on,TA}} = 9.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\text{off,TA}} = 2.7 \\times 10^{-3}\\ \\mathrm{s^{-1}}$. Compute $K_{D,\\mathrm{CD3}}$ and $K_{D,\\mathrm{TA}}$ in $\\mathrm{M}$, then report the dimensionless ratio $R = K_{D,\\mathrm{CD3}}/K_{D,\\mathrm{TA}}$.\n\nExpress the final answer as a pure number (no units), rounded to $3$ significant figures.", "solution": "The problem is scientifically and mathematically sound, well-posed, and contains all necessary information for a complete solution. We proceed with the derivation as requested.\n\nThe fundamental process is the reversible bimolecular reaction, where a free antigen, $A$, and a free BiTE arm, $B$, associate to form a complex, $C$. The reaction is described by the scheme:\n$$ A + B \\underset{k_{\\text{off}}}{\\stackrel{k_{\\text{on}}}{\\rightleftharpoons}} C $$\nHere, $k_{\\text{on}}$ is the second-order association rate constant and $k_{\\text{off}}$ is the first-order dissociation rate constant.\n\n1. Derivation of the differential rate equation for $[C](t)$.\nThe time evolution of the concentration of the complex, $[C]$, is governed by the law of mass action. The rate of change of $[C]$ is the difference between its rate of formation and its rate of consumption.\n\nThe forward reaction, $A + B \\xrightarrow{k_{\\text{on}}} C$, describes the formation of the complex. The rate of this elementary step, $v_f$, is proportional to the product of the reactant concentrations:\n$$ v_f = k_{\\text{on}} [A] [B] $$\n\nThe reverse reaction, $C \\xrightarrow{k_{\\text{off}}} A + B$, describes the dissociation of the complex. The rate of this elementary step, $v_r$, is proportional to the concentration of the complex:\n$$ v_r = k_{\\text{off}} [C] $$\n\nThe net rate of change of the complex concentration, $\\frac{d[C]}{dt}$, is the rate of formation minus the rate of consumption:\n$$ \\frac{d[C]}{dt} = v_f - v_r $$\nSubstituting the expressions for $v_f$ and $v_r$ gives the required differential rate equation:\n$$ \\frac{d[C]}{dt} = k_{\\text{on}} [A] [B] - k_{\\text{off}} [C] $$\n\n2. Derivation of the equilibrium dissociation constant, $K_D$.\nChemical equilibrium is the state where the net rate of reaction is zero. This means that the concentrations of all species are no longer changing with time. For the complex $C$, this condition is expressed as:\n$$ \\frac{d[C]}{dt} = 0 $$\nApplying this condition to the rate equation derived in the first part, we obtain:\n$$ k_{\\text{on}} [A]_{\\text{eq}} [B]_{\\text{eq}} - k_{\\text{off}} [C]_{\\text{eq}} = 0 $$\nwhere the subscript 'eq' denotes concentrations at equilibrium. Rearranging this equation yields:\n$$ k_{\\text{on}} [A]_{\\text{eq}} [B]_{\\text{eq}} = k_{\\text{off}} [C]_{\\text{eq}} $$\nThis can be rearranged into a ratio of concentrations:\n$$ \\frac{[A]_{\\text{eq}} [B]_{\\text{eq}}}{[C]_{\\text{eq}}} = \\frac{k_{\\text{off}}}{k_{\\text{on}}} $$\nThe equilibrium dissociation constant, $K_D$, is thermodynamically defined for the dissociation reaction $C \\rightleftharpoons A + B$ as the ratio of the product of equilibrium concentrations of the dissociated species to the equilibrium concentration of the complex:\n$$ K_D \\equiv \\frac{[A]_{\\text{eq}} [B]_{\\text{eq}}}{[C]_{\\text{eq}}} $$\nBy comparing the two expressions, we derive the relationship between the equilibrium dissociation constant and the kinetic rate constants:\n$$ K_D = \\frac{k_{\\text{off}}}{k_{\\text{on}}} $$\nThis relationship applies independently to each binding arm of the BiTE molecule under the specified conditions.\n\n3. Calculation of $K_{D,\\mathrm{CD3}}$, $K_{D,\\mathrm{TA}}$, and the ratio $R$.\nWe apply the derived formula to calculate the dissociation constants for both the CD3-binding arm and the tumor antigen (TA)-binding arm.\n\nFor the CD3-binding arm, the given constants are $k_{\\text{on,CD3}} = 2.8 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\text{off,CD3}} = 3.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$. The dissociation constant $K_{D,\\mathrm{CD3}}$ is:\n$$ K_{D,\\mathrm{CD3}} = \\frac{k_{\\text{off,CD3}}}{k_{\\text{on,CD3}}} = \\frac{3.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}}{2.8 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 1.25 \\times 10^{-7}\\ \\mathrm{M} $$\n\nFor the TA-binding arm, the given constants are $k_{\\text{on,TA}} = 9.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\text{off,TA}} = 2.7 \\times 10^{-3}\\ \\mathrm{s^{-1}}$. The dissociation constant $K_{D,\\mathrm{TA}}$ is:\n$$ K_{D,\\mathrm{TA}} = \\frac{k_{\\text{off,TA}}}{k_{\\text{on,TA}}} = \\frac{2.7 \\times 10^{-3}\\ \\mathrm{s^{-1}}}{9.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 0.3 \\times 10^{-8}\\ \\mathrm{M} = 3.0 \\times 10^{-9}\\ \\mathrm{M} $$\n\nFinally, we compute the dimensionless ratio $R = K_{D,\\mathrm{CD3}}/K_{D,\\mathrm{TA}}$:\n$$ R = \\frac{K_{D,\\mathrm{CD3}}}{K_{D,\\mathrm{TA}}} = \\frac{1.25 \\times 10^{-7}\\ \\mathrm{M}}{3.0 \\times 10^{-9}\\ \\mathrm{M}} = \\frac{1.25}{3.0} \\times 10^{2} \\approx 0.41666... \\times 100 = 41.666... $$\nThe problem requires the answer to be rounded to $3$ significant figures.\n$$ R \\approx 41.7 $$\nThis ratio indicates that the affinity of the BiTE for the tumor antigen is approximately $41.7$ times higher than its affinity for CD3, since a smaller $K_D$ corresponds to a higher binding affinity.", "answer": "$$\\boxed{41.7}$$", "id": "2837351"}, {"introduction": "While molecular affinity is essential, a BiTE's therapeutic effect is ultimately determined by its concentration at the site of action over time. This practice shifts our focus from the microscopic scale of receptor binding to the macroscopic scale of pharmacokinetics (PK), the study of how an organism affects a drug. By deriving a one-compartment PK model for a BiTE administered by continuous infusion, you will develop a foundational understanding of how key parameters like clearance ($CL$) and volume of distribution ($V$) govern a drug's steady-state concentration and the time required to reach it [@problem_id:2837296]. This exercise is a cornerstone for designing rational dosing strategies that maintain therapeutic drug levels in patients.", "problem": "A bispecific T cell engager (BiTE) antibody construct is administered to a patient by continuous intravenous infusion at a constant rate $R_{0}$. Assume linear pharmacokinetics (PK), described by a single, well-mixed compartment of constant apparent volume of distribution $V$, with linear systemic clearance $CL$. At time $t=0$, the infusion is initiated and the plasma concentration is $C(0)=0$. Using conservation of mass as the fundamental base and assuming no target-mediated drug disposition and instantaneous distribution within the compartment, derive the governing ordinary differential equation for the plasma concentration $C(t)$, solve for $C(t)$, identify the steady-state concentration, and then determine the time $t_{0.9}$ at which $C(t)$ first reaches $0.9$ of its steady-state value. Express $t_{0.9}$ in terms of $CL$ and $V$ only. Report time in hours if $CL$ is given in liters per hour and $V$ in liters. Provide your final answer as a single closed-form analytic expression.", "solution": "The problem as stated is scientifically grounded, well-posed, and contains sufficient information for a unique solution. We shall proceed with the derivation.\n\nThe fundamental principle is the conservation of mass within a single, well-mixed compartment of volume $V$. The rate of change of the amount of drug, $A(t)$, in the compartment is the difference between the rate of drug administration and the rate of drug elimination.\n\nThe rate of change of the drug amount is given by:\n$$\n\\frac{dA(t)}{dt} = (\\text{Rate In}) - (\\text{Rate Out})\n$$\nThe drug is administered by continuous intravenous infusion at a constant rate $R_{0}$. Thus, the rate in is simply $R_{0}$.\n$$\n\\text{Rate In} = R_{0}\n$$\nThe problem specifies linear systemic clearance, $CL$. This implies that the rate of elimination is directly proportional to the plasma concentration of the drug, $C(t)$.\n$$\n\\text{Rate Out} = CL \\cdot C(t)\n$$\nThe amount of drug in the compartment, $A(t)$, is related to the plasma concentration $C(t)$ and the apparent volume of distribution $V$ by the definition:\n$$\nA(t) = V \\cdot C(t)\n$$\nAssuming $V$ is constant, we can differentiate this expression with respect to time $t$:\n$$\n\\frac{dA(t)}{dt} = V \\frac{dC(t)}{dt}\n$$\nSubstituting these expressions into the mass balance equation yields the governing ordinary differential equation (ODE) for the plasma concentration $C(t)$:\n$$\nV \\frac{dC(t)}{dt} = R_{0} - CL \\cdot C(t)\n$$\nTo facilitate the solution, we rearrange this ODE into the standard form for a first-order linear differential equation:\n$$\n\\frac{dC(t)}{dt} + \\frac{CL}{V} C(t) = \\frac{R_{0}}{V}\n$$\nThis is a non-homogeneous linear ODE of the form $\\frac{dy}{dt} + P(t)y = Q(t)$, where $P(t) = \\frac{CL}{V}$ and $Q(t) = \\frac{R_{0}}{V}$ are constants. The term $\\frac{CL}{V}$ is the first-order elimination rate constant, which we can denote as $k_{e}$.\nThe solution can be found using an integrating factor, $I(t) = \\exp\\left(\\int \\frac{CL}{V} dt\\right) = \\exp\\left(\\frac{CL}{V} t\\right)$. Multiplying the ODE by $I(t)$:\n$$\n\\exp\\left(\\frac{CL}{V} t\\right) \\frac{dC(t)}{dt} + \\frac{CL}{V} \\exp\\left(\\frac{CL}{V} t\\right) C(t) = \\frac{R_{0}}{V} \\exp\\left(\\frac{CL}{V} t\\right)\n$$\nThe left side of the equation is the derivative of the product $C(t)I(t)$:\n$$\n\\frac{d}{dt}\\left[C(t) \\exp\\left(\\frac{CL}{V} t\\right)\\right] = \\frac{R_{0}}{V} \\exp\\left(\\frac{CL}{V} t\\right)\n$$\nIntegrating both sides with respect to $t$:\n$$\nC(t) \\exp\\left(\\frac{CL}{V} t\\right) = \\int \\frac{R_{0}}{V} \\exp\\left(\\frac{CL}{V} t\\right) dt = \\frac{R_{0}}{V} \\left(\\frac{V}{CL}\\right) \\exp\\left(\\frac{CL}{V} t\\right) + K_{int}\n$$\nwhere $K_{int}$ is the constant of integration. Simplifying and solving for $C(t)$:\n$$\nC(t) = \\frac{R_{0}}{CL} + K_{int} \\exp\\left(-\\frac{CL}{V} t\\right)\n$$\nTo determine $K_{int}$, we apply the initial condition given in the problem: at time $t=0$, the plasma concentration is $C(0)=0$.\n$$\nC(0) = 0 = \\frac{R_{0}}{CL} + K_{int} \\exp(0) = \\frac{R_{0}}{CL} + K_{int}\n$$\nThis gives $K_{int} = -\\frac{R_{0}}{CL}$. Substituting this back into the general solution for $C(t)$:\n$$\nC(t) = \\frac{R_{0}}{CL} - \\frac{R_{0}}{CL} \\exp\\left(-\\frac{CL}{V} t\\right)\n$$\nFactoring out the common term gives the explicit solution for the plasma concentration as a function of time:\n$$\nC(t) = \\frac{R_{0}}{CL} \\left(1 - \\exp\\left(-\\frac{CL}{V} t\\right)\\right)\n$$\nNext, we identify the steady-state concentration, $C_{ss}$. This is the concentration as time approaches infinity, $t \\to \\infty$.\n$$\nC_{ss} = \\lim_{t \\to \\infty} C(t) = \\lim_{t \\to \\infty} \\left[ \\frac{R_{0}}{CL} \\left(1 - \\exp\\left(-\\frac{CL}{V} t\\right)\\right) \\right]\n$$\nSince $CL > 0$ and $V > 0$, the exponential term $\\exp\\left(-\\frac{CL}{V} t\\right)$ approaches $0$ as $t \\to \\infty$. Therefore, the steady-state concentration is:\n$$\nC_{ss} = \\frac{R_{0}}{CL}\n$$\nThe problem requires finding the time $t_{0.9}$ at which the concentration $C(t)$ reaches $0.9$ of its steady-state value. We set up the equation:\n$$\nC(t_{0.9}) = 0.9 \\cdot C_{ss}\n$$\nSubstituting the expressions for $C(t)$ and $C_{ss}$:\n$$\n\\frac{R_{0}}{CL} \\left(1 - \\exp\\left(-\\frac{CL}{V} t_{0.9}\\right)\\right) = 0.9 \\left(\\frac{R_{0}}{CL}\\right)\n$$\nAssuming a non-zero infusion rate and clearance, the term $\\frac{R_{0}}{CL}$ cancels from both sides:\n$$\n1 - \\exp\\left(-\\frac{CL}{V} t_{0.9}\\right) = 0.9\n$$\nWe now solve for $t_{0.9}$. Rearranging the equation:\n$$\n\\exp\\left(-\\frac{CL}{V} t_{0.9}\\right) = 1 - 0.9 = 0.1\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\exp\\left(-\\frac{CL}{V} t_{0.9}\\right)\\right) = \\ln(0.1)\n$$\n$$\n-\\frac{CL}{V} t_{0.9} = \\ln(10^{-1}) = -\\ln(10)\n$$\nFinally, solving for $t_{0.9}$:\n$$\nt_{0.9} = \\frac{V}{CL} \\ln(10)\n$$\nThis expression gives the time $t_{0.9}$ exclusively in terms of the volume of distribution $V$ and the clearance $CL$, as required. The dimensional consistency is correct: if $V$ is in liters ($L$) and $CL$ is in liters per hour ($L/h$), the ratio $\\frac{V}{CL}$ has units of hours ($h$), which is appropriate for time.", "answer": "$$\\boxed{\\frac{V}{CL} \\ln(10)}$$", "id": "2837296"}, {"introduction": "The central challenge in developing many cancer immunotherapies, including BiTEs, is to maximize tumor cell killing while minimizing damage to healthy tissues. This advanced problem synthesizes the concepts of binding affinity and drug concentration into a quantitative framework for evaluating the therapeutic window. You will construct a model that links antigen expression levels on tumor versus normal cells to the probability of T cell activation, allowing you to define a safe and effective dosing range [@problem_id:2837361]. This exercise provides a powerful illustration of how quantitative systems pharmacology can be used to predict and mitigate the risk of on-target, off-tumor toxicity, a critical consideration in modern drug development.", "problem": "A bispecific T cell engager (BiTE) is designed to bind a tumor-associated antigen on target cells and Cluster of Differentiation 3 (CD3) on T cells in the T cell receptor (TCR) complex. The BiTE has a dissociation constant of $K_{A} = 10\\,\\mathrm{nM}$ for the tumor antigen and $K_{C} = 30\\,\\mathrm{nM}$ for CD3. A candidate antigen $X$ is expressed at $n_{\\text{tumor}} = 5.0 \\times 10^{4}$ copies per tumor cell and at $n_{\\text{normal}} = 5.0 \\times 10^{2}$ copies per vital normal cell. Assume a well-mixed environment where the free BiTE concentration is $C$ (in $\\mathrm{nM}$).\n\nUse the following fundamental bases:\n1) By the law of mass action and standard receptor occupancy, the per-epitope occupancy for each arm is $f_{A}(C) = \\dfrac{C}{C + K_{A}}$ and $f_{C}(C) = \\dfrac{C}{C + K_{C}}$.\n2) The expected number of BiTE molecules bound to the target cell antigen is $B(C,n) = n \\, f_{A}(C)$, where $n$ is the antigen copy number per cell.\n3) A minimal saturable synapse-signaling metric for T cell activation in a single encounter can be modeled as $S(C,n) = B(C,n) \\, f_{C}(C)$, and the per-encounter probability of cytotoxic activation is the Michaelis–Menten-like form $P_{\\text{act}}(C,n) = \\dfrac{S(C,n)}{S(C,n) + \\theta}$, with a fixed signaling threshold parameter $\\theta = 1.0 \\times 10^{3}$ in the same effective units as $S$.\n\nDefine efficacy as the condition $P_{\\text{act}}(C,n_{\\text{tumor}}) \\ge e_{\\min}$ with $e_{\\min} = 0.90$, and safety as the condition $P_{\\text{act}}(C,n_{\\text{normal}}) \\le r_{\\max}$ with $r_{\\max} = 0.10$.\n\nStarting only from the bases above, derive the analytical expressions needed to determine the minimum BiTE concentration $C_{\\min}$ that achieves efficacy and the maximum allowable concentration $C_{\\max}$ that maintains safety. Then compute the quantitative selectivity margin $M = \\dfrac{C_{\\max}}{C_{\\min}}$.\n\nExpress the final selectivity margin as a unitless real number and round your answer to three significant figures.", "solution": "Givens extracted verbatim are:\n- Dissociation constant for tumor antigen: $K_{A} = 10\\,\\mathrm{nM}$\n- Dissociation constant for CD3: $K_{C} = 30\\,\\mathrm{nM}$\n- Antigen copies per tumor cell: $n_{\\text{tumor}} = 5.0 \\times 10^{4}$\n- Antigen copies per normal cell: $n_{\\text{normal}} = 5.0 \\times 10^{2}$\n- Free BiTE concentration: $C$ (in nM)\n- Per-epitope occupancy for antigen arm: $f_{A}(C) = \\dfrac{C}{C + K_{A}}$\n- Per-epitope occupancy for CD3 arm: $f_{C}(C) = \\dfrac{C}{C + K_{C}}$\n- Expected bound BiTEs: $B(C,n) = n \\, f_{A}(C)$\n- Synapse-signaling metric: $S(C,n) = B(C,n) \\, f_{C}(C)$\n- Probability of cytotoxic activation: $P_{\\text{act}}(C,n) = \\dfrac{S(C,n)}{S(C,n) + \\theta}$\n- Signaling threshold parameter: $\\theta = 1.0 \\times 10^{3}$\n- Efficacy condition: $P_{\\text{act}}(C,n_{\\text{tumor}}) \\ge e_{\\min}$ with $e_{\\min} = 0.90$\n- Safety condition: $P_{\\text{act}}(C,n_{\\text{normal}}) \\le r_{\\max}$ with $r_{\\max} = 0.10$\n\nThe objective is to derive the minimum concentration for efficacy, $C_{\\min}$, and the maximum concentration for safety, $C_{\\max}$, and then compute their ratio, the selectivity margin $M$.\n\nFirst, we construct the full expression for the activation probability $P_{\\text{act}}(C,n)$. By substituting the given definitions, we have:\n$$S(C,n) = B(C,n) \\, f_{C}(C) = \\left( n \\, f_{A}(C) \\right) f_{C}(C) = n \\left( \\frac{C}{C + K_{A}} \\right) \\left( \\frac{C}{C + K_{C}} \\right) = \\frac{n C^2}{(C + K_{A})(C + K_{C})}$$\nThen, the activation probability is:\n$$P_{\\text{act}}(C,n) = \\frac{S(C,n)}{S(C,n) + \\theta} = \\frac{\\frac{n C^2}{(C + K_{A})(C + K_{C})}}{\\frac{n C^2}{(C + K_{A})(C + K_{C})} + \\theta} = \\frac{nC^2}{nC^2 + \\theta(C + K_{A})(C + K_{C})}$$\nTo find the concentration $C$ that corresponds to a given activation probability $P$, we must solve the equation $P_{\\text{act}}(C,n) = P$. It is algebraically simpler to first solve for the signaling metric $S$. From $P = \\frac{S}{S+\\theta}$, we rearrange to find $S(1-P) = P\\theta$, which gives the critical signaling level:\n$$S_{crit} = \\frac{P\\theta}{1-P}$$\nNow, we set $S(C,n) = S_{crit}$:\n$$\\frac{n C^2}{(C + K_{A})(C + K_{C})} = S_{crit}$$\nThis equation can be rearranged into a quadratic form $aC^2+bC+c=0$:\n$$n C^2 = S_{crit}(C^2 + (K_A + K_C)C + K_A K_C)$$\n$$(n - S_{crit}) C^2 - S_{crit}(K_A + K_C)C - S_{crit}K_A K_C = 0$$\nThe physically meaningful solution for the concentration $C$ must be positive. Using the quadratic formula, we find:\n$$C = \\frac{S_{crit}(K_A + K_C) + \\sqrt{\\left(S_{crit}(K_A + K_C)\\right)^2 + 4(n - S_{crit})(S_{crit}K_A K_C)}}{2(n - S_{crit})}$$\nWe have chosen the positive root for the numerator. For this solution to be positive, the denominator $n-S_{crit}$ must also be positive, which we will verify for each case. The function $S(C,n)$ is monotonically increasing with $C$ for $C>0$. Therefore, an inequality of the form $P_{\\text{act}} \\ge P$ is equivalent to $C \\ge C_{\\text{solution}}$, and $P_{\\text{act}} \\le P$ is equivalent to $C \\le C_{\\text{solution}}$.\n\nTo find $C_{\\min}$, we analyze the efficacy condition: $P_{\\text{act}}(C,n_{\\text{tumor}}) \\ge e_{\\min}$. This sets the minimum required concentration.\nHere, $P = e_{\\min} = 0.90$, $n=n_{\\text{tumor}}=5.0 \\times 10^4$. The critical signaling level for efficacy is:\n$$S_{\\text{eff}} = \\frac{e_{\\min}\\theta}{1-e_{\\min}} = \\frac{0.90 \\times (1.0 \\times 10^3)}{1-0.90} = \\frac{900}{0.10} = 9000$$\nThe coefficients of the quadratic equation for $C$ are determined using $n_{\\text{tumor}}=5.0 \\times 10^4$, $S_{crit}=S_{\\text{eff}}=9000$, $K_A=10$, and $K_C=30$.\n- $a = n_{\\text{tumor}} - S_{\\text{eff}} = 50000 - 9000 = 41000$ (This is positive as required.)\n- $b = -S_{\\text{eff}}(K_A + K_C) = -9000(10+30) = -360000$\n- $c = -S_{\\text{eff}}K_A K_C = -9000(10 \\times 30) = -2700000$\nThe quadratic equation is $41000 C^2 - 360000 C - 2700000 = 0$, which simplifies to $41 C^2 - 360 C - 2700 = 0$.\nThe solution gives $C_{\\min}$:\n$$C_{\\min} = \\frac{360 + \\sqrt{(-360)^2 - 4(41)(-2700)}}{2(41)} = \\frac{360 + \\sqrt{129600 + 442800}}{82} = \\frac{360 + \\sqrt{572400}}{82}$$\n$$C_{\\min} \\approx \\frac{360 + 756.571}{82} \\approx 13.6167\\,\\mathrm{nM}$$\n\nTo find $C_{\\max}$, we analyze the safety condition: $P_{\\text{act}}(C,n_{\\text{normal}}) \\le r_{\\max}$. This sets the maximum allowable concentration.\nHere, $P = r_{\\max} = 0.10$, $n=n_{\\text{normal}}=5.0 \\times 10^2$. The critical signaling level for safety is:\n$$S_{\\text{safe}} = \\frac{r_{\\max}\\theta}{1-r_{\\max}} = \\frac{0.10 \\times (1.0 \\times 10^3)}{1-0.10} = \\frac{100}{0.90} = \\frac{1000}{9}$$\nThe coefficients of the quadratic are determined using $n_{\\text{normal}}=500$, $S_{crit}=S_{\\text{safe}}=\\frac{1000}{9}$, $K_A=10$, and $K_C=30$.\n- $a = n_{\\text{normal}} - S_{\\text{safe}} = 500 - \\frac{1000}{9} = \\frac{4500-1000}{9} = \\frac{3500}{9}$ (Positive, as required.)\n- $b = -S_{\\text{safe}}(K_A + K_C) = -\\frac{1000}{9}(40) = -\\frac{40000}{9}$\n- $c = -S_{\\text{safe}}K_A K_C = -\\frac{1000}{9}(300) = -\\frac{300000}{9}$\nThe equation is $\\frac{3500}{9} C^2 - \\frac{40000}{9} C - \\frac{300000}{9} = 0$, which simplifies to $35 C^2 - 400 C - 3000 = 0$, and further to $7 C^2 - 80 C - 600 = 0$.\nThe solution gives $C_{\\max}$:\n$$C_{\\max} = \\frac{80 + \\sqrt{(-80)^2 - 4(7)(-600)}}{2(7)} = \\frac{80 + \\sqrt{6400 + 16800}}{14} = \\frac{80 + \\sqrt{23200}}{14}$$\n$$C_{\\max} \\approx \\frac{80 + 152.315}{14} \\approx 16.5940\\,\\mathrm{nM}$$\n\nThe therapeutic window is the interval $[C_{\\min}, C_{\\max}]$, which exists because $C_{\\min} < C_{\\max}$. The selectivity margin $M$ is the ratio of these concentrations:\n$$M = \\frac{C_{\\max}}{C_{\\min}} \\approx \\frac{16.5940}{13.6167} \\approx 1.21865$$\nRounding to three significant figures, we get $M = 1.22$.", "answer": "$$\\boxed{1.22}$$", "id": "2837361"}]}